Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7275)
All Articles published online
|
Publishing Process of This Article
|
Jul 28, 2015 (publication date) through Nov 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Vonghia L, Francque S. Cross talk of the immune system in the adipose tissue and the liver in non-alcoholic steatohepatitis: Pathology and beyond. World J Hepatol 2015; 7(15): 1905-1912 [PMID: 26244065 DOI: 10.4254/wjh.v7.i15.1905] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v7/i15/1905.htm |
| Number | Citing Articles |
| 1 |
A. L. L. Rocha, L. C. Faria, T. C. M. Guimarães, G. V. Moreira, A. L. Cândido, C. A. Couto, F. M. Reis. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis. Journal of Endocrinological Investigation 2017; 40(12): 1279 doi: 10.1007/s40618-017-0708-9
|
| 2 |
Marta Iruarrizaga-Lejarreta, Fernando Bril, Mazen Noureddin, Pablo Ortiz, Shelly C. Lu, José M. Mato, Cristina Alonso. Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease. 2019; : 423 doi: 10.1007/978-3-030-11748-1_16
|
| 3 |
Tereza C. M. Fontes-Cal, Rafael T. Mattos, Nayara I. Medeiros, Bruna F. Pinto, Mayara Belchior-Bezerra, Bruna Roque-Souza, Walderez O. Dutra, Teresa C. A. Ferrari, Paula V. T. Vidigal, Luciana C. Faria, Cláudia A. Couto, Juliana A. S. Gomes. Crosstalk Between Plasma Cytokines, Inflammation, and Liver Damage as a New Strategy to Monitoring NAFLD Progression. Frontiers in Immunology 2021; 12 doi: 10.3389/fimmu.2021.708959
|
| 4 |
Joselyn N. Allen, Adwitia Dey, Jingwei Cai, Jingtao Zhang, Yuan Tian, Mary Kennett, Yanling Ma, T. Jake Liang, Andrew D. Patterson, Pamela A. Hankey-Giblin. Metabolic Profiling Reveals Aggravated Non-Alcoholic Steatohepatitis in High-Fat High-Cholesterol Diet-Fed Apolipoprotein E-Deficient Mice Lacking Ron Receptor Signaling. Metabolites 2020; 10(8): 326 doi: 10.3390/metabo10080326
|
| 5 |
Mirella Pastore, Alessandra Gentilini, Fabio Marra. Non-Alcoholic Fatty Liver Disease. 2020; : 97 doi: 10.1007/978-3-319-95828-6_6
|
| 6 |
Yang Yang, Xian Liu, Hui Chen, Pengjun Wang, Songhui Yao, Bin Zhou, Ronghua Yin, Changyan Li, Chutse Wu, Xiaoming Yang, Miao Yu. HPS protects the liver against steatosis, cell death, inflammation, and fibrosis in mice with steatohepatitis. The FEBS Journal 2022; 289(17): 5279 doi: 10.1111/febs.16430
|
| 7 |
Jana Hundertmark, Oliver Krenkel, Frank Tacke. Adapted Immune Responses of Myeloid-Derived Cells in Fatty Liver Disease. Frontiers in Immunology 2018; 9 doi: 10.3389/fimmu.2018.02418
|
| 8 |
Kook Hwan Kim, Myung-Shik Lee. Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches. Frontiers in Endocrinology 2018; 9 doi: 10.3389/fendo.2018.00485
|
| 9 |
Cheng Ma, Cheng Wang, Yafang Zhang, Honglin Zhou, Yunxia Li. Potential Natural Compounds for the Prevention and Treatment of Nonalcoholic
Fatty Liver Disease: A Review on Molecular Mechanisms. Current Molecular Pharmacology 2022; 15(6): 846 doi: 10.2174/1874467215666211217120448
|
| 10 |
Stergios A. Polyzos, Jannis Kountouras, Christos S. Mantzoros. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019; 92: 82 doi: 10.1016/j.metabol.2018.11.014
|
| 11 |
Y Ilan, K Shailubhai, A Sanyal. Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASH. Clinical and Experimental Immunology 2018; 193(3): 275 doi: 10.1111/cei.13159
|
| 12 |
Jared S. Farrar, Rebecca K. Martin. Non-Alcoholic Steatohepatitis. Methods in Molecular Biology 2022; 2455: 103 doi: 10.1007/978-1-0716-2128-8_10
|
| 13 |
Shendong Wang, Junhao Yin, Zhaojun Liu, Xin Liu, Ge Tian, Xijian Xin, Yiming Qin, Xiujing Feng. Metabolic disorders, inter-organ crosstalk, and inflammation in the progression of metabolic dysfunction-associated steatotic liver disease. Life Sciences 2024; 359: 123211 doi: 10.1016/j.lfs.2024.123211
|
| 14 |
Marco Arrese, Daniel Cabrera, Alexis M. Kalergis, Ariel E. Feldstein. Innate Immunity and Inflammation in NAFLD/NASH. Digestive Diseases and Sciences 2016; 61(5): 1294 doi: 10.1007/s10620-016-4049-x
|
| 15 |
Safa Tahmasebi, Hassan Neishaboori, Davood Jafari, Elham Faghihzadeh, Abdolreza Esmaeilzadeh, Abbas Mirshafiey. The effects of guluronic acid (G2013), a new emerging treatment, on inflammatory factors in nonalcoholic steatohepatitis patients under in vitro conditions. Immunopharmacology and Immunotoxicology 2021; 43(5): 562 doi: 10.1080/08923973.2021.1954946
|
| 16 |
Manon Bourinet, Rodolphe Anty, Philippe Gual, Carmelo Luci. Roles of innate lymphoid cells in metabolic and alcohol-associated liver diseases. JHEP Reports 2024; 6(2): 100962 doi: 10.1016/j.jhepr.2023.100962
|
| 17 |
Guilherme R. Romualdo, Letícia Cardoso Valente, Jéssica Luri Hisano de Souza, Josias Rodrigues, Luís Fernando Barbisan. Modifying effects of 2,4-D and Glyphosate exposures on gut-liver-adipose tissue axis of diet-induced non-alcoholic fatty liver disease in mice. Ecotoxicology and Environmental Safety 2023; 268: 115688 doi: 10.1016/j.ecoenv.2023.115688
|
| 18 |
Maria Arconzo, Elena Piccinin, Antonio Moschetta. Increased risk of acute liver failure by pain killer drugs in NAFLD: Focus on nuclear receptors and their coactivators. Digestive and Liver Disease 2021; 53(1): 26 doi: 10.1016/j.dld.2020.05.034
|
| 19 |
Feliciano Chanana Paquissi. Immune Imbalances in Non-Alcoholic Fatty Liver Disease: From General Biomarkers and Neutrophils to Interleukin-17 Axis Activation and New Therapeutic Targets. Frontiers in Immunology 2016; 7 doi: 10.3389/fimmu.2016.00490
|